Objective The chemotactic factor CXCL16 plays an important role in atherogenesis. The aim of this study is to explore the effects of atorvastatin and fenofibrate on atherosclerosis and expression of CXCL16. Methods ApoE knockout mice were divided into three groups including atorvastatin group, fenofibrate group and control group. After feeding with " Western" diet for 8 weeks, all mice were euthanized. Paraffin sections of aorta with HE staining were performed for microscopic examination and analysis of atherosclerotic lesions. Expression of CXCL16 and CXCR6 was detected by immunohistochemical method and quantitative analysis by using digital quantitative analysis software. Real - Time PCR was used to quantify CXCL16 mRNA expression. Results The atherosclerotic lesions were remarkably alleviated in atorvastatin and fenofibrate groups than those of control group, and the ratio of area of plaque to area of vessel lumen was significantly deceased. The expression of CXCL16 and CXCR6 in aorta was alleviated in atorvastatin group and fenofibrate group compared with those of control group. CXCL16 mRNA expression was significantly decreased in mice of fenofibrate group, but it did not happen in mice of atorvastatin group. Conclusion Both atorvastatin and fenofibrate can attenuate atherosclerosis and down - regulate expression of CXCL16 protein in ApoE knockout mice. CXCL16 mRNA expression can be inhibited by fenofibrate but not by atorvastatin.%目的 探讨两类调脂药物阿托伐他汀及非诺贝特对动脉CXC趋化因子配体16(CXCL16)表达的影响.方法 研究对象采用ApoE基因敲除小鼠,随机分为阿托伐他汀组、非诺贝特组及对照组,给予药物干预8周后,取小鼠主动脉采用医学图像分析系统测量动脉斑块大小,免疫组化半定量分析主动脉弓CXCL16及CXCR6的蛋白表达,实时定量聚合酶链反应测定CXCL16 mRNA.结果 阿托伐他汀及非诺贝特组动脉硬化程度均较对照组明显减轻,斑块面积减小;阿托伐他汀组及非诺贝特组主动脉弓CXCL16和CXCR6的平均光密度值均较对照组减低;非诺贝特组CXCL16 mRNA表达减低(P<0.05),而阿托伐他汀组CXCL16 mRNA表达较对照组无显著变化.结论 阿托伐他汀及非诺贝特均可以减轻ApoE基因敲除小鼠动脉粥样硬化病变,下调CXCL16蛋白表达,但非诺贝特不同于阿托伐他汀可以有效减低CXCL16 mRNA的表达,两者作用机制可能不同.
展开▼
